Medicinal products for the treatment of Alzheimer's disease and other dementias

  • Email
  • Help
Current effective version

Revision 1 - Adopted guideline

Currently under revision - see below

Reference numberCPMP/EWP/553/1995 Rev. 1
Effective from01/02/2009
KeywordsAlzheimer’s disease, dementia, Lewy body disease, Parkinson’s disease, disease modifying treatment, prevention, symptomatic treatment, vascular dementia
DescriptionThis document provides guidance on the development of medicinal products for the treatment of dementia and its subtypes. It addresses Alzheimer’s disease, vascular dementia, dementia associated with Parkinson’s disease and Lewy body disorder, Huntington’s disease or fronto-temporal dementia.

Document history

Revision 2


Draft guideline

Concept paper

Concept paper

Published: 01/02/2016

Deadline for comments: 31/07/2016

Published: 31/10/2013

Published: 26/03/2012

Revision 1 

Current version

Adopted guideline

Draft guideline

Concept paper

In operation: 01/02/2009–present

Published: 19/07/2007

Published: 17/11/2005

Related content

How helpful is this page?

Average rating:

 Based on 11 ratings

Add your rating:

See all ratings
2 ratings
3 ratings
2 ratings
2 ratings
2 ratings

Tell us more